Disc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients

The expanded access program (EAP) is available to eligible patients with erythropoietic protoporphyria (EPP) and provides access to bitopertin ...

AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical Milestones

AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced a significant milestone in its pancreatic cancer development program, with enrollment of the final subject, barring ...

Ultralife (ULBI) Q1 2026 Earnings Transcript

Friday, May 8, 2026 at 8:30 a.m. ET Consolidated Revenue -- $47.4 million, down 6.6% from the previous year, driven by declines in both segments.
The Manila Times

UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus

Publication adds to previously reported findings from Phase 3 PHOENYCS GO study, demonstrating statistically significant ...

WW (WW) Q1 2026 Earnings Call Transcript

Felicia DellaFortuna said, "Behavioral subscribers were 2.5 million at the end of Q1 2026, reflecting a 25% year-over-year decline," and Core continues to face "secular headwinds and saw incremental ...
Federal News Network

The 3 goals of OMB’s rewrite of grants regulations

The Office of Management and Budget is updating 2 CFR 200 for a second time in two years and changes would give political appointees direct approval authority.